Therapeutic potential of cannabinoids in CNS disease

CNS Drugs

Volumn 17, Issue 3, 2003, Pages 179-202

  Croxford, J Ludovic ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANANDAMIDE; ANTIEMETIC AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DEXANABINOL; DRONABINOL; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; LIGAND; NABILONE; NEUROTRANSMITTER; REACTIVE OXYGEN METABOLITE; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR;

ANXIETY DISORDER; APPETITE; BRAIN INJURY; CANCER PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY; DOPAMINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; OBESITY; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEDATION; SPASTICITY; SPINAL CORD INJURY; STROKE; SYMPTOM; TREMOR; VOMITING; WASTING SYNDROME;

ANALGESIA; ANOREXIA; CANNABINOIDS; CENTRAL NERVOUS SYSTEM DISEASES; ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; HUMANS; OBESITY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; VOMITING;

EID: 0037218316     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317030-00004     Document Type: Review

References (219)

1. Vincent BJ, McQuiston DJ, Einhorn LH, et al. Review of cannabinoids and their anti-emetic effectiveness. Drugs 1983; 25 Suppl. 1: 52-62
2. Gaoni Y, Mechoulam R. Isolation, structure elucidation and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7
3. Howlett AC, Barth F, Bonnet G, et al. International union of pharmacology. XXVII: classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202
4. Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13
5. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9
6. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5
7. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346 (6284): 561-4
8. Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 1986; 29 (3): 307-13
9. Pacheco MA, Ward SJ, Childers SR. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res 1993; 603 (1): 102-10
10. Yamaguchi F, Macrae AD, Brenner S. Molecular cloning of two cannabinoid type 1-like receptor genes from the puffer fish Fugu rubripes. Genomics 1996; 35 (3): 603-5
11. De Petrocellis L, Melck D, Bisogno T, et al. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999; 92 (1): 377-87
12. Stefano GB, Salzet B, Salzet M. Identification and characterization of the leech CNS cannabinoid receptor: coupling to nitric oxide release. Brain Res 1997; 753 (2): 219-24
13. Chang MC, Berkery D, Schuel R, et al. Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Reprod Dev 1993; 36 (4): 507-16
14. Bisogno T, Ventriglia M, Milone A, et al. Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim Biophys Acta 1997; 1345 (3): 338-48
15. McPartland J, Di Marzo V, De Petrocellis L, et al. Cannabinoid receptors are absent in insects. J Comp Neurol 2001; 436 (4): 423-9
16. Shire D, Carillon C, Kaghad M, et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995; 270 (8): 3726-31
17. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74 (2): 129-80
18. Herkenham M, Lynn AB, Johnson MR. et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11 (2): 563-83
19. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990; 87 (5): 1932-6
20. Dove Pettit DA, Harrison MP, Olson JM, et al. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 1998; 51 (3): 391-402
21. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992; 48 (3): 655-68
22. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991; 258 (2): 517-23
23. Hohmann AG, Martin WJ, Tsou K, et al. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci 1995; 56 (23-24): 2111-8
24. Sallan SE, Zinberg NE, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293 (16): 795-7
25. London SW, McCarthy LE, Borison HL. Suppression of cancer chemotherapy-induced vomiting in the cat by nabilone, a synthetic cannabinoid. Proc Soc Exp Biol Med 1979; 160 (4): 437-40
26. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232 (1): 54-61
27. Holland M, John Challiss RA, Standen NB, et al. Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle. Br J Pharmacol 1999; 128 (3): 597-604
28. Croci T, Manara L, Aureggi G, et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 1998; 125 (7): 1393-5
29. Rice W, Shannon JM, Burton F, et al. Expression of a brain-type cannabinoid receptor (CB1) in alveolar Type II cells in the lung: regulation by hydrocortisone. Eur J Pharmacol 1997; 327 (2-3): 227-32
30. Straiker AJ, Maguire G, Mackie K, et al. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci 1999; 40 (10): 2442-8
31. Porcella A, Casellas P, Gessa GL, et al. Cannabinoid receptor CBI mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Mol Brain Res 1998; 58 (1-2): 240-5
32. Griffin G, Fernando SR, Ross RA, et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997; 339 (1): 53-61
33. Lu Q, Straiker A, Maguire G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis Neurosci 2001; 17 (1): 91-5
34. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 1996; 93 (9): 3984-9
35. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77 (2): 299-318
36. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38 (2): 151-78
37. Barth F, Rinaldi-Carmona M. The development of cannabinoid antagonists. Curr Med Chem 1999; 6 (8): 745-55
38. Terranova JP, Storme JJ, Lafon N, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacologia 1996; 126 (2): 165-72
39. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994; 268 (3): 1612-23
40. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17 (14): 5327-33
41. Maneuf YP, Brotchie JM. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 1997; 120 (8): 1397-8
42. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48 (3): 443-50
43. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992; 89 (9): 3825-9
44. Mackie K, Lai Y, Westenbroek R, et al. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in ART20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995; 15 (10): 6552-61
45. Bouaboula M, Poinot-Chazel C, Bourrie B, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995; 312 (Pt 2): 637-41
46. Liu J, Gao B, Mirshahi F, et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 346 (Pt 3): 835-40
47. Ishac EJ, Jiang L, Lake KD, et al. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996; 118 (8): 2023-8
48. Kathmann M, Bauer U, Schlicker E, et al. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch Pharmacol 1999; 359 (6): 466-70
49. Nakazi M, Bauer U, Nickel T, et al. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2000; 361 (1): 19-24
50. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588-92
51. Shen M, Piser TM, Seybold VS, et al. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996; 16 (14): 4322-34
52. Breivogel CS, Griffin G, Di Matzo V, et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60 (1): 155-63
53. Di Marzo V, Beivogel CS, Tao Q, et al. Levels, metabolism, and pharmacological activity in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75: 2434-44
54. Jarai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 1999; 96 (24): 14136-41
55. Showalter VM, Compton DR, Martin BR, et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996; 278 (3): 989-99
56. Schmid PC, Krebsbach RJ, Perry SR, et al. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett 1995; 375 (1-2): 117-20
57. Sugiura T, Kondo S, Sukagawa A, et al. N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. J Lipid Mediat Cell Signal 1996; 14 (1-3): 51-6
58. Felder CC, Nielsen A, Briley EM, et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Letters 1996; 393 (2-3): 231-5
59. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15 (2): 300-2
60. Yang HY, Karoum F, Felder C, et al. GC/MS analysis of anandamide and quantification of N-arachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat. J Neurochem 1999; 72 (5): 1959-68
61. Deutsch DG, Goligorsky MS, Schmid PC, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997; 100 (6): 1538-46
62. Schmid PC, Paria BC, Krebsbach RJ, et al. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci U S A 1997; 94 (8): 4188-92
63. Giuffrida A, Piomelli D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett 1998; 422 (3): 373-6
64. Hansen HS, Moesgaard B, Hansen HH, et al. Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Lipids 1999; 34 Suppl.: S327-30
65. Giuffrida A, Parsons LH, Kerr TM, et al. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nat Neurosci 1999; 2 (4): 358-63
66. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389 (6653): 816-24
67. Nagy I, Rang H. Noxious heat activates all capsaicin-sensitive and also a sub-population of capsaicin-insensitive dorsal root ganglion neurons. Neuroscience 1999; 88 (4): 995-7
68. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400 (6743): 452-7
69. Smart D, Gunthorpe MJ, Jerman JC, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVRI). Br J Pharmacol 2000; 129 (2): 227-30
70. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50 (1): 83-90
71. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388 (6644): 773-8
72. Goparaju SK, Ueda N, Yamaguchi H, et al. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 1998; 422 (1): 69-73
73. Bisogno T, Maurelli S, Melck D, et al. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 1997; 272 (6): 3315-23
74. DiMarzo V, Fontana A, Cadas H, et al. Formationand inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372 (6507): 686-91
75. Calignano A, La Rana G, Giuffrida A, et al. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394 (6690): 277-81
76. Facci L, Dal Toso R, Romanello S, et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995; 92 (8): 3376-80
77. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 2001; 419 (2-3): 19I-8
78. Di Marzo V, Melck D, Orlando P, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 2001; 358 (Pt 1): 249-55
79. De Petrocellis L, Davis JB, Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 2001; 506 (3): 253-6
80. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001; 98 (7): 3662-5
81. Porter AC, Sauer J-M, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301 (3): 1020-4
82. Beltramo M, Stella N, Calignano A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277 (5329): 1094-7
83. Maccarrone M, van der Stelt M, Rossi A, et al. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem 1998; 273 (48): 32332-9
84. Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 2000; 11 (6): 1231-5
85. Maccarrone M, Bari M, Lorenzon T, et al. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem 2000; 275 (18): 13484-92
86. Beltramo M, de Fonseca FR, Navarro M, et al. Reversal of dopamine D (2) receptor responses by an anandamide transport inhibitor. J Neurosci 2000; 20 (9): 3401-7
87. Zygmunt PM, Chuang H, Movahed P, et al. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 2000; 396 (1): 39-42
88. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384: 83-7
89. Deutsch DG, Glaser ST, Howell JM, et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol Chem 2001; 276 (10): 6967-73
90. Egertova M, Giang DK, Cravatt BF, et al. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B Biol Sci 1998; 265 (1410): 2081-5
91. Maccarrone M, Bari M, Menichelli A, et al. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett 1999; 447 (2-3): 277-82
92. Maccarrone M, Valensise H, Bari M, et al. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 2000; 355 (9212): 1326-9
93. Di Marzo V, Bisogno T, De Petrocellis L, et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 1999; 264 (1): 258-67
94. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signalling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001; 98 (16): 9371-6
95. Gifford AN, Bruneus M, Lin S, et al. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). Eur J Pharmacol 1999; 383 (1): 9-14
96. Eissenstat MA, Bell MR, D'Ambra TE, et al. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 1995; 38 (16): 3094-105
97. Huffman JW, Yu S, Showalter V, et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 1996; 39 (20): 3875-7
98. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350 (2-3): 240-4
99. Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284 (2): 644-50
100. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1: evidence for a new model of receptor/ligand interactions. J Biol Chem 1997; 272 (35): 22330-9
101. MacLennan SJ, Reynen PH, Kwan J, et al. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 1998; 124 (4): 619-22
102. Bouaboula M, Desnoyer N, Carayon P, et al. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol Pharmacol 1999; 55 (3): 473-80
103. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001; 178: 107-15
104. Cannabinoids in multiple sclerosis trial [online]. Available from URL: http://www.cannabis-trial.Plymouth.ac.uk [Accessed 2002 Mar 26]
105. GW Pharmaceuticals [online]. Available from URL: http://www.gwpharm.com [Accessed 2002 Mar 26]
106. Fox SH, Kellett M, Moore AP, et al. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002; 17 (1): 145-9
107. Sieradzan KA, Fox SH, Hill M, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001; 57 (11): 2108-11
108. Frankel JP, Hughes A, Lees AJ, et al. Marijuana for parkinsonian tremor [letter]. J Neurol Neurosurg Psychiatry 1990; 53 (5): 436
109. Jain AK, Ryan JR, McMahon FG, et al. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21 (8-9 Suppl.): 320S-6S
110. Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52 (5): 483-6
111. Pharmos Corporation [online]. Available from URL: http://www.pharmoscorp.com [Accessed 2002 Mar 26]
112. Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled phase II clinical trial. Crit Care Med 2002; 30 (3): 548-54
113. Fishman RHB. Cannabinoid derivative protects neurons [abstract]. Lancet 1996; 348 (9039): 1436
114. Dalton R. Californian centre will test medical uses of cannabis [abstract]. Nature 2000; 407 (6800): 6
115. Anonymous. Medical marijuana study in San Francisco: pays $1000, 25 days in hospital. AIDS Treat News 1998; 296: 3-4
116. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14 (1): 7-14
117. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10 (2): 89-97
118. Muller-Vahl KR, Koblenz A, Jobges M, et al. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 2001; 34 (1): 19-24
119. National Multiple Sclerosis Society [online]. Available from URL: http://nationalmssociety.org [Accessed 2003 Jan 2]
120. Noth J. Trends in the pathophysiology and pharmacotherapy of spasticity. J Neurol 1991; 238 (3): 131-9
121. Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000; 81 (2): 164-9
122. Goodkin DE. Current disease-modifying therapies in multiple sclerosis. In: Raine CS, McFarlin HF, Tourtellotte WW, editors. Multiple sclerosis: clinical and pathogenetic basis. London: Chapman and Hall, 1997: 309-23
123. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38 (1): 44-8
124. Black JA, Dib-Hajj S, Baker D, et al. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc Natl Acad Sci U S A 2000; 97 (21): 11598-602
125. Turski L, Klockgether T, Schwarz M, et al. Substantia nigra: a site of action of muscle relaxant drugs. Ann Neurol 1990; 28 (3): 341-8
126. Szabo B, Wallmichrath I, Mathonia P, et al. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 2000; 97 (1): 89-97
127. Garcia-Gil L, de Miguel R, Romero J, et al. Perinatal delta9-tetrahydrocannabinol exposure augmented the magnitude of motor inhibition caused by GABA (B), but not GABA (A), receptor agonists in adult rats. Neurotoxicol Teratol 1999; 21 (3): 277-83
128. Baker D, O'Neill JK, Gschmeissner SE, et al. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 1990; 28 (3): 261-70
129. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404 (6773): 84-7
130. Brooks JW, Pryce G, Bisogno T, et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur J Pharmacol 2002; 439 (1-3): 83-92
131. Melck D, Bisogno T, De Petrocellis L, et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 1999; 262 (1): 275-84
132. Klein TW, Newton C, Zhu W, et al. Delta9-tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med 1995; 209 (3): 205-12
133. Klein TW, Lane B, Newton CA, et al. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000; 225 (1): 1-8
134. Klein TW, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998; 19 (8): 373-81
135. Maimone D, Gregory S, Arnason BG, et al. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991; 32 (1): 67-74
136. Selmaj K, Raine CS, Cannella B, et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87 (3): 949-54
137. Mageed RA, Adams G, Woodrow D, et al. Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor. Gene Ther 1998; 5 (12): 1584-92
138. Triantaphyllopoulos KA, Williams RO, Tailor H, et al. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999; 42 (1): 90-9
139. Croxford JL, Feldmann M, Chernajovsky Y, et al. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL- 10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J Immunol 2001; 166 (6): 4124-30
140. Croxford JL, Triantaphyllopoulos KA, Neve RM, et al. Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J Immunol 2000; 164 (5): 2776-81
141. Croxford JL, Triantaphyllopoulos K, Podhajcer OL, et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998; 160 (10): 5181-7
142. Racke MK, Dhib-Jalbut S, Cannella B, et al. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol 1991; 146 (9): 3012-7
143. Lyman WD, Sonett JR, Brosnan CF, et al. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989; 23 (1): 73-81
144. Wirguin I, Mechoulam R, Breuer A, et al. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994; 28 (3): 209-14
145. Burnette-Curley D, Cabral GA. Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9-tetrahydrocannabinol. Proc Soc Exp Biol Med 1995; 210 (1): 64-76
146. Achiron A, Miron S, Lavie V, et al. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000; 102 (1): 26-31
147. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6 (1): 67-70
148. Werner P, Pitt D, Raine CS. Glutamate excitotoxicity: a mechanism for axonal damage and oligodendrocyte death in multiple sclerosis? J Neural Transm Suppl 2000; 60: 375-85
149. Marjama-Lyons J, Koller W. Tremor-predominant Parkinson's disease: approaches to treatment. Drugs Aging 2000; 16 (4): 273-8
150. Herkenham M, Lynn AB, de Costa BR, et al. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991; 547 (2): 267-74
151. Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 1996; 22 (4): 382-5
152. Gough AL, Olley JE. Catalepsy induced by intrastriatal injections of delta9-THC and 11-OH-delta9-THC in the rat. Neuropharmacology 1978; 17 (2): 137-44
153. DiMarzo V, Hill MP, Bisogno T, et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000; 14 (10): 1432-8
154. Vingerhoets FJ, Schulzer M. Calne DB, et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41 (1): 58-64
155. Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998; 95 (14): 8268-73
156. Biegon A. Neuroprotective activity of HU-211, a novel nonpsychotropic synthetic cannabinoid [abstract]. Ann N Y Acad Sci 1995; 765: 314
157. Olney JW. Glutamate-induced neuronal necrosis in the infant mouse hypothalamus: an electron microscopic study. J Neuropathol Exp Neurol 1971; 30 (1): 75-90
158. Sinor AD, Irvin SM, Greenberg DA. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 2000; 278 (3): 157-60
159. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998; 54 (3): 459-62
160. Leker RR, Shohami E, Abramsky O, et al. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci 1999; 162 (2): 114-9
161. van der Stelt M, Veldhuis WB, van Haaften GW, et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 2001; 21 (22): 8765-71
162. van der Stelt M, Veldhuis WB, Bar PR, et al. Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001; 21 (17): 6475-9
163. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413 (6855): 527-31
164. Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19 (8): 2987-95
165. Lavie G, Teichner A, Shohami E, et al. Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brain Res 2001; 901 (1-2): 195-201
166. Hansen HH, Schmid PC, Bittigau P, et al. Anandamide, but not 2-arachidonylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 2001; 78: 1415-27
167. Shohami E, Gallily R, Mechoulam R, et al. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 1997; 72 (2): 169-77
168. Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur J Pharmacol 2000; 406: R5-7
169. Walker JM, Huang SM, Strangman NM, et al. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 1999; 96 (21): 12198-203
170. Farquhar-Smith WP, Egertova M, Bradbury EJ, et al. Cannabinoid CB (1) receptor expression in rat spinal cord. Mol Cell Neurosci 2000; 15 (6): 510-21
171. Walker JM, Hohmann AG, Martin WJ, et al. The neurobiology of cannabinoid analgesia. Life Sci 1999; 65 (6/7): 665-73
172. Herzberg U, Eliav E, Bennett GJ, et al. The analgesic effects of R (+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221 (2-3): 157-60
173. Richardson JD, Aanonsen L, Hargreaves KM, Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345 (2): 145-53
174. Fox A, Kesingland A, Gentry C, et al. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92 (1-2): 91-100
175. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001; 133 (4): 586-94
176. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75 (1): 111-9
177. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997; 319 (2-3): R3-4
178. Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain?: a qualitative
179. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992; 262 (1): 10-8
180. Darmani NA. Delta (9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB (1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001; 24 (2): 198-203
181. Darmani NA. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol 2001; 430 (1): 49-58
182. Van Sickle MD, Oland LD, Ho W, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001; 121 (4): 767-74
183. Parker LA, Kemp SW. Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). Neuroreport 2001; 12 (4): 749-51
184. Parker LA, Mechoulam R, Schlievert C, Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002; 13 (5): 567-70
185. Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323 (7303): 16-21
186. Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT (3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001; 7 (2): 199-213
187. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986; 61 (5): 502-5
188. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79 (6): 946-52
189. Mechoulam R. Recent advantages in cannabinoid research. Forsch Komplementarmed 1999; 6 Suppl. 3: 16-20
190. Hirst RA, Lambert DG, Notcutt WG. Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth 1998; 81 (1): 77-84
191. Cat LK, Coleman RL. Treatment for HIV wasting syndrome. Ann Pharmacother 1994; 28 (5): 595-7
192. Plasse TF, Gorter RW, Krasnow SH, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40 (3): 695-700
193. Struwe M, Kaempfer SH, Geiger CJ, et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993; 27 (7-8): 827-31
194. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134 (6): 1151-4
195. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999; 143 (3): 315-7
196. Rowland NE, Mukherjee M, Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 2001; 159 (1): 111-6
197. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63 (8): PL113-7
198. Sanofi Synthelabo US [online]. Available from URL: http://www.sanofi-synthelabous.com [Accessed 2002 Mar 26]
199. DiMarzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410 (6830): 822-5
200. Busto U, Bendayan R, Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet 1989; 16 (1): 1-26
201. Maykut MO. Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9 (3): 209-38
202. Agurell S, Halldin M, Lindgren J-E, et al. Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other compounds with emphasis on man. Pharmacol Rev 1986; 38 (10): 21-43
203. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83 (4): 637-49
204. Kovasznay B, Fleischer J, Tanenberg-Karant M, et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997; 23 (2): 195-201
205. Paton WDM, Pertwee RG. The actions of cannabis in man. In: Mechoulam R, editor. Marijuana: chemistry, pharmacology, metabolism and clinical effects. New York: Academic Press, 1973: 288-334
206. Nahas G. General toxicity of cannabis. In: Nahas GG, Latour C, editors. Cannabis: pathophysiology, epidemiology, detection. Boca Raton (FL): CRC Press, 1993: 5-17
207. Heishman SJ, Arasteh K, Stitzer ML. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav 1997; 58 (1): 93-101
208. Pertwee RG. Tolerance to and dependence on psychotropic cannabinoids. In: Pratt JA, editor. The biological basis of drug tolerance and dependence. New York: Academic Press, 1991: 232-63
209. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352 (9140): 1611-6
210. Niederhoffer N, Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 1999; 126 (2): 457-66
211. Leweke FM, Giuffrida A, Wurster U, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10 (8): 1665-9
212. Hepler RS, Frank IR. Marijuana smoking and intraocular pressure [abstract]. JAMA 1971; 217 (10): 1392
213. Ashton H, Golding J, Marsh VR, et al. The seed and the soil: effect of dosage, personality and starting state on the response to delta 9 tetrahydrocannabinol in man. Br J Clin Pharmacol 1981; 12 (5): 705-20
214. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997; 56 (4): 803-7
215. Leweke FM, Schneider U, Radwan M, et al. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 2000; 66 (1): 175-81
216. Zuardi AW, Morais SL, Guimaraes FS, et al. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56 (10): 485-6
217. Penta JS, Poster DS, Bruno S, et al. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol 1981; 21 (8-9 Suppl.): 11S-22S
218. Lichtman AH, Peart J, Poklis JL, et al. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol 2000; 399 (2-3): 141-9
219. Lemberger L. Tetrahydrocannabinol metabolism in man. Drug Metab Dispos 1973; 1: 461-8